Napigen
1 known investors
Napigen develops technology for mitochondrial and chloroplast genome editing. The company operates in the biotechnology and genetic engineering sector.
Investors · 1
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2022 | $225K |
| Department of Agriculture (USDA) | Phase I | 2020 | $100K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
- Napigen Advancing Organelle Genome Editing Technology for Crop Hybrid Seed Production | GenomeWebgenomeweb.com · 2022
- Genetics startup Napigen raises nearly $8Mdelawarebusinesstimes.com · 2022
- Organelle Genome Editing Startup Napigen Raises $7.9M | GenomeWebgenomeweb.com · 2022